Resilience
Biomanufacturing CDMO improving access to complex medicines
Biotech
📍 Blue Ash, OH
Founded 2020
Current Valuation
$9.4B
as of 2023-Q1
UNICORN
Resilience (legal name National Resilience) is a biomanufacturing contract development and manufacturing organization (CDMO) building end-to-end manufacturing capacity for biologics, cell & gene therapies, and other complex medicines. Founded in 2020 and last priced at $9.4B in early 2023, it operates a network of US and Canadian manufacturing facilities.
Company Profile
Growth
Expanding cell & gene therapy and ADC manufacturing capacity
Last Round
Series D — $625M (Jan 2023) · Lead: GIC
IPO Status
no imminent plans
Founders & Key People
Rahul SinghviRobert Nelsen
Investors
GIC · ARCH Venture Partners · 8VC · Andreessen Horowitz · NEA
Products
- Biologics manufacturing
- Cell & gene therapy CDMO
- Drug substance & drug product
- Fill-finish
Competitors
Lonza · Catalent · Samsung Biologics · WuXi Biologics
BiotechBiomanufacturingCDMODecacorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q1. Refreshed quarterly.